An observational study in Acute Ischemic Stroke and Acute Haemorrhagic Stroke, sponsored by Assiut University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Assiut University · Observational
Searching electrical activity registered by EEG in acute ischemic and hemorrhagic stroke and comparing these parameters to the post-stroke recovery patterns to investigate the role of EEG as a differentiation tool and as a predictor of post-stroke recovery.
In this study, EEG will be performed on each patient included; within 72 hours of the onset of the stroke. The EEG device will be used within the intended use as described in the user manuals. The electrodes are put on the patient's head, and the EEG signal is recorded for several minutes; the amplifier is used to amplify the EEG signal and reduce artifacts. A complete EEG and data will be collected at baseline and on follow-up to observe the differences in EEG patterns to perform a qualitative assessment of the EEG results.
EEG patterns depend on the size and location of acute ischemic stroke, including generalized or focal slowing or both and epileptiform discharges. Abnormal neuronal activity is determined by comparing a part of the patient's brain not affected by stroke to a part of the patient's brain affected by stroke. Moreover, Abnormal blood flow is interpreted by comparing the abnormal EEG patterns in the areas of infarctions or hemorrhage to the normal brain tissue signals. The aim is to compare electric waveforms from an EEG device between patients with acute ischemic and acute hemorrhagic stroke (at baseline which is within 72 hours of the onset of acute ischemic and acute hemorrhagic stroke and through study completion, an average of 3 to 6 months).
2,612 studies on the registry are indexed under Ischemic Stroke; 971 are open to participants now.
This study's planned enrollment of 300 is close to the median of 300 across 771 observational studies indexed under Ischemic Stroke.
Browse Ischemic Stroke studies →Assiut University is the lead sponsor of 5,078 studies on the registry; 2,178 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients with acute Ischemic stroke: ischemic arteria cerebri media infarct confirmed by MRI, or acute Hemorrhagic stroke: spontaneous intraparenchymal bleeding confirmed by CT, onset \<72 hours before expected time of performing EEG.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with ischemic arteria cerebri media infarct confirmed by MRI.
Patients with spontaneous intraparenchymal bleeding confirmed by CT.
Proportion of Participants With Focal Slowing in the Stroke-Affected Hemisphere
Presence of focal slowing (e.g., increased delta or theta activity) in the stroke-affected hemisphere versus the unaffected hemisphere. Patterns categorized as "ischemic" or "hemorrhagic."; this will be measured in percentage (%).
Time frame: Baseline (within 72 hours of stroke onset)
Proportion of Participants With Interhemispheric Asymmetry in EEG Waveforms
Qualitative assessment of EEG asymmetry between affected and unaffected hemispheres at baseline. Frequency of each will be measured in percentage (%).
Time frame: Baseline (within 72 hours of stroke onset)
Proportion of Participants With Absent or Diminished EEG Reactivity
Absence or reduction in EEG reactivity to external stimuli (e.g., auditory, tactile) in the affected hemisphere; this will be measures by precentage (%).
Time frame: Baseline (within 72 hours of stroke onset)
Proportion of Participants With Epileptiform Activity on EEG
Presence of epileptiform discharges (e.g., spikes or sharp waves) on EEG in the stroke-affected hemisphere; thsi will be measured by precentage (%).
Time frame: Baseline (within 72 hours of stroke onset)
Correlation Between Baseline EEG Findings and Functional Recovery
Association between initial qualitative EEG abnormalities (e.g., focal slowing, asymmetry) and functional outcomes measured by standardized scales (e.g., Modified Rankin Scale) at 6 months; measured by Correlation coefficient (r).
Time frame: Phase I (Baseline EEG assessment) and Phase III (3 to 6 month follow-up functional evaluation)
Prediction of Post-Stroke Seizures Based on EEG Findings
Proportion of participants with specific EEG abnormalities (e.g., epileptiform activity) at baseline who develop post-stroke seizures within 3 to 6 months, measured by percentage (%).
Time frame: Phase I (Baseline EEG assessment) and Phase III (3 to 6 month follow-up functional evaluation)
Plan to share: Undecided
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.